Cochrane · systematic review · CD012722
Methotrexate for psoriatic arthritis
Wilsdon, TD, Whittle, SL, Thynne, TRJ, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
MusculoskeletalAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
16
current version
GRADE rated
11
No studies
5
Included studies
NR
No studies 5 · 31.3%Ungraded 0 · 0%Very low 6 · 37.5%Low 5 · 31.3%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Methotrexate compared to placebo for psoriatic arthritis (up to six months)
Population: psoriatic arthritis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Disease response Methotrexate vs placebo | RR 1.76 [1.14, 2.7] | 1 study · 221 participants | Low Downgraded: risk of bias, imprecision |
Function Methotrexate vs placebo | no estimate extracted | 1 study · 221 participants | Low Downgraded: risk of bias, imprecision |
Health‐related quality of life ‐ not reported Methotrexate vs placebo | no estimate extracted | NR | No studies |
Disease activity Methotrexate vs placebo | no estimate extracted | 1 study · 221 participants | Low Downgraded: risk of bias, imprecision |
Radiographic progression ‐ not measured Methotrexate vs placebo | no estimate extracted | NR | No studies |
Serious adverse events (SAEs) assessed by number of events Methotrexate vs placebo | RR 0.26 [0.03, 2.26] | 3 studies · 293 participants | Low Downgraded: risk of bias, imprecision |
Withdrawals due to adverse events (WAEs) assessed by number of events Methotrexate vs placebo | RR 1.32 [0.51, 3.42] | 3 studies · 293 participants | Low Downgraded: risk of bias, imprecision |
Methotrexate compared to other DMARDs for psoriatic arthritis (up to six months)
Population: psoriatic arthritis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Disease response (leflunomide) Methotrexate vs other DMARDs | RR 1.05 [0.77, 1.45] | 1 study · 30 participants | Very low Downgraded: risk of bias, imprecision |
Function (leflunomide) Methotrexate vs other DMARDs | no estimate extracted | 1 study · 31 participants | Very low Downgraded: risk of bias, imprecision |
Health‐related quality of life ‐ not measured Methotrexate vs other DMARDs | no estimate extracted | NR | No studies |
Disease activity ‐ not measured Methotrexate vs other DMARDs | no estimate extracted | NR | No studies |
Radiographic progression ‐ not measured Methotrexate vs other DMARDs | no estimate extracted | NR | No studies |
Serious adverse events (leflunomide) assessed by number of events Methotrexate vs other DMARDs | no estimate extracted | 2 studies · 61 participants | Very low Downgraded: risk of bias, imprecision |
Withdrawals due to adverse events (leflunomide) assessed by number of events Methotrexate vs other DMARDs | no estimate extracted | 2 studies · 61 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse events (ciclosporin A) assessed by number of events Methotrexate vs other DMARDs | no estimate extracted | 1 study · 35 participants | Very low Downgraded: risk of bias, imprecision |
Withdrawals due to adverse events (ciclosporin A) assessed by number of events Methotrexate vs other DMARDs | RR 1.26 [0.33, 4.82] | 1 study · 35 participants | Very low Downgraded: risk of bias, imprecision |